Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_4

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 4Post-market surveillance

3(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 43 (100.0%)

Trials by Status

completed267%

terminated133%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_4

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

NCT00223938

completedphase_4

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)

NCT00224081

completedphase_4

Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure

NCT01925703

Clinical Trials (3)

Showing 3 of 3 trials

NCT00223938Phase 4

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

Terminated

NCT00224081Phase 4

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)

Completed

NCT01925703Phase 4

Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3